# Kappa calibration worksheet

For each case: read the query, the gold label, and the system's answer with its claims resolved to real source text. Fill in your own pass/partial/fail for each listed property, the same rubric the judge used (docs/DECISION_LOG.md, "Answer-set scoring rubric"). This is deliberately blind: no judge verdict is shown anywhere in this file.

Rubric reminder: **pass** = fully correct; **partial** = right direction but a tier off (direction), or cites both sources without stating they conflict (disagreement), or 70-90% of claims grounded (groundedness); **fail** = wrong/no citation/missed the conflict entirely/wrongly refused or wrongly answered.

---

## atm_at_lymphoid_tumor_ord_001

**Query:** What does the literature report about ATM kinase activity level and tumor risk in ataxia-telangiectasia patients?

**Gold direction:** increased risk with complete loss of ATM kinase activity; residual kinase activity is protective  
**Gold strength:** cohort of 296 genetically confirmed A-T patients from the British Isles and the Netherlands, 66 developed a malignant tumour (47 lymphoid, 19 non-lymphoid)

**System said not_found:** False
**System answer:**
> The literature reports that childhood lymphoid and brain tumours in A‑T patients occur almost exclusively when ATM kinase activity is absent, whereas patients with low‑level residual activity have a markedly lower risk, indicating a protective effect of even modest ATM kinase function [2]. Studies of larger A‑T cohorts were undertaken to relate presence versus absence of kinase activity to cancer risk [4].

**System's cited claims, resolved to real source text:**

1. Claim: "Childhood tumours in A‑T are associated almost exclusively with absence of ATM kinase activity"
   Cited source (PMC3170966, body): "We show here that development of childhood tumours (lymphoid and brain) in A-T patients is associated almost exclusively with absence of ATM kinase activity. Conversely our findings suggest that expression of some residual ATM kinase activity has a strongly protective effect against tumour development in A-T in childhood. The source of the residual ATM kinase activity was a low level of either normal ATM or mutant ATM. The origin of the retained kinase activity in 25 patients (median age, 29 years) was the presence of the IVS40-1050A>G splice site mutation (McConville et al, 1996; Stewart et al, 2001; Sutton et al, 2004) expressing a low level (∼5%) of normal ATM. Despite the protection against tumour development provided by retained ATM kinase activity, two developed tumours, although significantly only in adulthood (one patient had a T-ALL at 17 years of age; the other patient had a testicular seminoma at an age of 27 years and a cerebral diffuse large B-cell lymphoma at an age of 34 years). This apparent contradiction may be reconciled if the level of ATM kinase activity in these IVS40-1050A>G-carrying patients is close to a threshold of ATM kinase activity that would normally be tumour suppressive."

2. Claim: "Residual ATM kinase activity provides a protective effect against tumour development"
   Cited source (PMC3170966, body): "We show here that development of childhood tumours (lymphoid and brain) in A-T patients is associated almost exclusively with absence of ATM kinase activity. Conversely our findings suggest that expression of some residual ATM kinase activity has a strongly protective effect against tumour development in A-T in childhood. The source of the residual ATM kinase activity was a low level of either normal ATM or mutant ATM. The origin of the retained kinase activity in 25 patients (median age, 29 years) was the presence of the IVS40-1050A>G splice site mutation (McConville et al, 1996; Stewart et al, 2001; Sutton et al, 2004) expressing a low level (∼5%) of normal ATM. Despite the protection against tumour development provided by retained ATM kinase activity, two developed tumours, although significantly only in adulthood (one patient had a T-ALL at 17 years of age; the other patient had a testicular seminoma at an age of 27 years and a cerebral diffuse large B-cell lymphoma at an age of 34 years). This apparent contradiction may be reconciled if the level of ATM kinase activity in these IVS40-1050A>G-carrying patients is close to a threshold of ATM kinase activity that would normally be tumour suppressive."

3. Claim: "The relationship between ATM kinase activity (present vs absent) and cancer risk was investigated in large A‑T cohorts"
   Cited source (PMC3170966, body): "In contrast, heterozygous female ATM mutation carriers in A-T families have an increased risk of developing breast cancer, without any evidence for an increased risk of lymphoid tumours (Swift et al, 1991; Geoffroy-Perez et al, 2001; Olsen et al, 2001; Thompson et al, 2005). Ataxia-telangiectasia shows substantial phenotypic heterogeneity, both neurological (Hiel et al, 2006; Verhagen et al, 2009) and immunological (Staples et al, 2008). There is also substantial allelic heterogeneity, and a consideration of possible mechanisms for tumour development in A-T patients must take into account the expression of either different mutant ATM proteins, or combinations of two ATM proteins with or without kinase activity. We sought to establish the relationship between absence or presence of ATM kinase activity and cancer risk, based on a large cohort of A-T patients from the UK and the Netherlands."

**Your verdicts (pass/partial/fail):**
- direction: pass
- groundedness: pass (With the un-truncated text, Claim 3 is now fully supported by the sentence confirming the study sought to establish the relationship based on a large cohort)
- says_not_found (should NOT have refused): pass

---

## atm_c2023c_t_breast_neg_001

**Query:** What does the literature report about ATM c.2023C>T and breast cancer risk?

**Gold:** negative case, expected_not_found = true (this variant/condition pair is deliberately absent from the corpus).

**System said not_found:** True
**System answer:**
> None of the provided excerpts mention the specific ATM c.2023C>T variant in relation to breast cancer risk; the excerpts discuss ATM in broader contexts or other cancers, but do not address this particular mutation.

**System's cited claims:** none.

**Your verdicts (pass/partial/fail):**
- says_not_found: pass

---

## atm_c6832c_a_ovarian_neg_001

**Query:** What does the literature report about ATM c.6832C>A and ovarian cancer risk?

**Gold:** negative case, expected_not_found = true (this variant/condition pair is deliberately absent from the corpus).

**System said not_found:** True
**System answer:**
> The provided excerpts do not mention the specific ATM c.6832C>A variant in relation to ovarian cancer risk; they only discuss ATM generally or other variants.

**System's cited claims:** none.

**Your verdicts (pass/partial/fail):**
- says_not_found: pass

---

## atm_c7570g_c_risk_class_disagree_001

**Query:** What does the literature report about ATM c.7570G>C and breast cancer risk classification?

**Gold direction:** high_risk_vs_moderate  
**Gold strength:** moderate

**Gold disagreement (what the sources actually conflict about):** PMC10092731 (2023) argues that ATM c.7570G>C should be reclassified from the general 'moderate-risk' category to 'high-risk', noting that while ATM is 'generally placed in the moderate-risk category with a combined estimation of 2-fold risk', specific variants like c.7570G>C with dominant-negative effects have 'up to 60% lifetime breast cancer by the age of 70 years'. PMC8973562 (2022) reports overall ATM pathogenic variants show hazard ratio of only 1.32 (95% CI), supporting ATM as moderate-risk. The disagreement is about whether c.7570G>C is a special high-risk variant vs standard moderate-risk ATM variant.

**System said not_found:** False
**System answer:**
> The literature reports that ATM c.7570G>C is significantly associated with breast cancer and is classified as a high‑risk allele, with an odds ratio of about 8.5 (95% CI 1.04‑62.46, P = .018) indicating a strong effect, contrary to the usual moderate‑risk view of ATM variants [1,2].

**System's cited claims, resolved to real source text:**

1. Claim: "ATM c.7570G>C significantly associates with breast cancer and the risk is estimated as high."
   Cited source (PMC10092731, body): "As ATM c.7570G>C is recurrently encountered in the genetic counseling units in patients with increased risk for breast cancer, there is a need for clearer risk estimates. Here, using both selected breast cancer families from the clinics and so far the largest Northern Finnish unselected breast cancer case cohort (n = 1822), we show that c.7570G>C significantly associates with breast cancer and the risk is estimated as high. This is the first allele‐specific breast cancer risk estimation for ATM c.7570G>C variant in Finnish population, and the result should be taken into consideration in genetic counseling."

2. Claim: "The variant has an odds ratio of 8.5 (95% CI = 1.04‑62.46, P = .018) and is placed among high‑risk alleles for breast cancer."
   Cited source (PMC10092731, abstract): "ATM is generally described as a moderate‐risk breast cancer susceptibility gene. However, some of ATM variants might encounter higher risk. ATM c.7570G>C, p.Ala2524Pro, (rs769142993) is a pathogenic Finnish founder variant causative for recessively inherited ataxia‐telangiectasia. At cellular level, it has been reported to have a dominant‐negative effect. ATM c.7570G>C has recurrently been described in Finnish breast cancer families and unselected case cohorts collected from different parts of the country, but the rarity of the allele (MAF 0.0002772 in Finns) and lack of confirming segregation analyses have prevented any conclusive risk estimates. Here, we describe seven families from genetic counseling units with ATM c.7570G>C variant showing co‐segregation with breast cancer. Further analysis of the unselected breast cancer cohort from Northern Finland (n = 1822), a geographical region previously indicated to have enrichment of the variant, demonstrated that c.7570G>C significantly associates with breast cancer, and the risk is estimated as high (odds ratio [OR] = 8.5, 95% confidence interval [CI] = 1.04‐62.46, P = .018). Altogether, these results place ATM c.7570G>C variant among the high‐risk alleles for breast cancer, which should be taken into consideration in genetic counseling."

**Your verdicts (pass/partial/fail):**
- direction: partial (Presents the high-risk view without adequately balancing the moderate-risk counter-evidence)
- groundedness: pass
- disagreement: fail (The system missed the conflict entirely, ignoring the moderate-risk perspective in the gold standard)
- says_not_found (should NOT have refused): pass

---

## atm_variants_controversy_disagree_001

**Query:** What does the literature report about the overall role of ATM variants in breast cancer susceptibility and what is the level of evidence for ATM as a breast cancer gene?

**Gold direction:** mixed_evidence  
**Gold strength:** moderate

**Gold disagreement (what the sources actually conflict about):** PMC7786920 (2021 systematic review and meta-analysis) states in abstract: 'ATM gene contributes to repair damaged DNA and to regulate cell cycle; therefore, ATM variants seem to increase breast cancer risk; however, the results are controversial. So we conducted a systematic review and meta-analysis to clarify the pooled association between various ATM variants and the risk of breast cancer.' The systematic review itself acknowledges and documents conflicting findings across individual studies - some showing 2-5 fold increased risk while others show no significant association. PMC137944 (2002 workshop) similarly states: 'The role of ataxia-telangiectasia mutated (ATM) heterozygosity in cancer is uncertain. In vitro studies of cells from ATM heterozygotes provide strong evidence of radiation sensitivity. Some, but not all, clinical studies suggest an increased risk of breast cancer among ATM gene carriers.' The core disagreement is whether ATM heterozygosity genuinely increases breast cancer risk (results disputed across studies).

**System said not_found:** False
**System answer:**
> The excerpts report that ATM is frequently implicated as a low‑penetrance susceptibility gene for breast cancer, but the overall evidence has been contradictory. Recent large epidemiological and molecular studies have provided conclusive evidence that ATM mutations that cause ataxia‑telangiectasia are breast‑cancer susceptibility alleles, while other ATM variant classes lack supporting evidence [1][2][4].

**System's cited claims, resolved to real source text:**

1. Claim: "ATM is frequently involved as a low‑penetrance breast cancer susceptibility gene and evidence is contradictory"
   Cited source (PMC2386480, abstract): "The ATM gene has been frequently involved in hereditary breast cancer as a low-penetrance susceptibility gene but evidence regarding the role of ATM as a breast cancer susceptibility gene has been contradictory."

2. Claim: "Recent large studies provide conclusive evidence that ATM mutations causing A‑T are breast cancer susceptibility alleles"
   Cited source (PMC2386480, body): "The incidence of breast cancer in Chile is still increasing but the mortality rate in the last decade has remained constant. Early detection contributes to mortality reduction and genetic testing may identify high-risk individuals. Mutations in BRCA1 and BRCA2 genes (BRCA1/2) have been identified as high penetrance alleles. However, these alleles explain only a small fraction of familial breast cancers [1,2]. We have previously screened for germ line mutations in BRCA1/2, 64 Chilean families with several cases of breast and/or ovarian cancer [3]. Only 15.6% of these presented mutations in one of these two genes. The most widely accepted model proposes that familial breast cancer susceptibility is a consequence of a small number of mutations in BRCA1/2 and a much larger variability in ethnic-specific genes of moderate and/or low penetrance [4]. The Ataxia-Telangiectasia Mutated gene (ATM) has been frequently involved in hereditary breast cancer as a low-penetrance susceptibility gene. The ATM kinase has an essential role in maintaining genomic integrity. It is a key activator of the cellular responses to DNA double-strand breaks [5]. Individuals heterozygous for ATM mutations have been reported to have an increased risk for female breast cancer. A number of studies have searched for germ line ATM mutations in breast cancer cases and/or compared the frequency of common ATM variants among breast cancer cases to population controls, but evidence regarding the role of ATM as a breast cancer susceptibility gene has been contradictory [6,7]. Recently, large epidemiological and molecular studies have finally provided conclusive evidence that ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles [6,8]. There was no evidence that other classes of ATM variants confer a risk of breast cancer [8]. A common ATM variant IVS38-8T>C in cis with the 5557G>A ATM variant, has been suggested to be associated with bilateral breast cancer [9]. The 5557G>A variant has previously been reported in the homozygous state to associate with enhanced clinical radiosensitivity in breast cancer patients [10-12]."

3. Claim: "No evidence that other classes of ATM variants confer breast cancer risk"
   Cited source (PMC2386480, body): "The incidence of breast cancer in Chile is still increasing but the mortality rate in the last decade has remained constant. Early detection contributes to mortality reduction and genetic testing may identify high-risk individuals. Mutations in BRCA1 and BRCA2 genes (BRCA1/2) have been identified as high penetrance alleles. However, these alleles explain only a small fraction of familial breast cancers [1,2]. We have previously screened for germ line mutations in BRCA1/2, 64 Chilean families with several cases of breast and/or ovarian cancer [3]. Only 15.6% of these presented mutations in one of these two genes. The most widely accepted model proposes that familial breast cancer susceptibility is a consequence of a small number of mutations in BRCA1/2 and a much larger variability in ethnic-specific genes of moderate and/or low penetrance [4]. The Ataxia-Telangiectasia Mutated gene (ATM) has been frequently involved in hereditary breast cancer as a low-penetrance susceptibility gene. The ATM kinase has an essential role in maintaining genomic integrity. It is a key activator of the cellular responses to DNA double-strand breaks [5]. Individuals heterozygous for ATM mutations have been reported to have an increased risk for female breast cancer. A number of studies have searched for germ line ATM mutations in breast cancer cases and/or compared the frequency of common ATM variants among breast cancer cases to population controls, but evidence regarding the role of ATM as a breast cancer susceptibility gene has been contradictory [6,7]. Recently, large epidemiological and molecular studies have finally provided conclusive evidence that ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles [6,8]. There was no evidence that other classes of ATM variants confer a risk of breast cancer [8]. A common ATM variant IVS38-8T>C in cis with the 5557G>A ATM variant, has been suggested to be associated with bilateral breast cancer [9]. The 5557G>A variant has previously been reported in the homozygous state to associate with enhanced clinical radiosensitivity in breast cancer patients [10-12]."

**Your verdicts (pass/partial/fail):**
- direction: pass
- groundedness: pass (The un-truncated text now fully supports all claims regarding conclusive evidence for A-T mutations and lack of evidence for other variants)
- disagreement: pass
- says_not_found (should NOT have refused): pass

---

## brca2_c7435_7439delacaaa_pancreatic_neg_001

**Query:** What does the literature report about BRCA2 c.7435_7439delACAAA and pancreatic cancer risk?

**Gold:** negative case, expected_not_found = true (this variant/condition pair is deliberately absent from the corpus).

**System said not_found:** True
**System answer:**
> The provided excerpts discuss BRCA2 and pancreatic cancer risk in general, but none mention the specific variant c.7435_7439delACAAA, so the literature does not establish a reported effect for this variant.

**System's cited claims:** none.

**Your verdicts (pass/partial/fail):**
- says_not_found: pass

---

## brca2_pancreatic_risk_ord_001

**Query:** What does the literature report about BRCA1/BRCA2 mutations and pancreatic cancer risk?

**Gold direction:** increased risk  
**Gold strength:** background association; approximately 4-7% of pancreatic cancer patients carry germline BRCA1/2 mutations

**System said not_found:** False
**System answer:**
> The excerpts report that germline BRCA1 and BRCA2 mutations raise pancreatic cancer risk, with BRCA2 conferring a higher risk than BRCA1. Relative risk estimates range from up to ~4‑fold for BRCA1 and up to ~20‑fold for BRCA2, and lifetime risks are about 1% for BRCA1 carriers and 5‑10% for BRCA2 carriers [2][5][6][7].

**System's cited claims, resolved to real source text:**

1. Claim: "BRCA1 and BRCA2 mutations increase pancreatic cancer risk"
   Cited source (PMC5155186, body): "Association of BRCA1/2 mutations with susceptibility to breast and ovarian cancer has been investigated for years. It is estimated that about 60% of women with BRCA1/2 mutations have developed breast cancer[14]. A woman who carries a germline BRCA1/2 mutation could be 5 times more likely to develop breast cancer than one who does not carry any BRCA1/2 mutation[15]. Men who have BRCA1/2 mutations are more likely to have prostate or pancreatic cancers. Men are 3.5 times and 8.6 times more likely to develop prostate cancer for BRCA1 and BRCA2 mutation carriers by age 65, respectively[16]. Similar to prostate cancer, BRCA1/2 poses a risk of pancreatic cancer development. Overall, BRCA1 mutation increases the risk by 0- to 4.11-fold, while the BRCA2 mutation increases the risk by 2.13- to 21.7-fold[17]."

2. Claim: "BRCA2 mutation confers higher risk than BRCA1"
   Cited source (PMC11135687, body): "Approximately 3% to 10% of individuals diagnosed with pancreatic adenocarcinoma exhibit a positive familial history of pancreatic cancer, with an estimated 10% to 20% of pancreatic adenocarcinomas attributed to hereditary factors [2,27]. In unselected cases of pancreatic adenocarcinoma, pathogenic mutations in BRCA2 are identified in up to 2%, while mutations in BRCA1 are observed in 1% or less. In the Ashkenazi Jewish population with pancreatic cancer, BRCA mutations are detected in up to 13.7% of unselected cases [17,28]. Within familial pancreatic cancer, defined by the presence of two or more first-degree relatives affected with pancreatic cancer, BRCA2 mutations are discerned in about 5% to 10% of cases, and BRCA1 mutations are found in approximately 1%. Consequently, BRCA1 and BRCA2 emerge as the predominant contributors to familial pancreatic cancer [29,30]. Carriers of BRCA2 mutations face a lifetime risk of pancreatic cancer ranging from 5% to 10%. Meanwhile, mutations in BRCA1 are associated with a two to fourfold increased risk [3,31]."

3. Claim: "Relative risk estimates: up to ~4‑fold for BRCA1, up to ~20‑fold for BRCA2"
   Cited source (PMC5155186, body): "Association of BRCA1/2 mutations with susceptibility to breast and ovarian cancer has been investigated for years. It is estimated that about 60% of women with BRCA1/2 mutations have developed breast cancer[14]. A woman who carries a germline BRCA1/2 mutation could be 5 times more likely to develop breast cancer than one who does not carry any BRCA1/2 mutation[15]. Men who have BRCA1/2 mutations are more likely to have prostate or pancreatic cancers. Men are 3.5 times and 8.6 times more likely to develop prostate cancer for BRCA1 and BRCA2 mutation carriers by age 65, respectively[16]. Similar to prostate cancer, BRCA1/2 poses a risk of pancreatic cancer development. Overall, BRCA1 mutation increases the risk by 0- to 4.11-fold, while the BRCA2 mutation increases the risk by 2.13- to 21.7-fold[17]."

4. Claim: "Lifetime risk ~1% for BRCA1 carriers, ~5‑10% for BRCA2 carriers"
   Cited source (PMC8835700, body): "Pathogenic BRCA1/2 variants increase the risk of breast, ovarian, pancreatic, prostate, and other cancers. BRCA1/2 mutant carriers have a relatively low risk of pancreatic cancer compared to breast and ovarian cancer. In FPC registry studies, BRCA2 mutant carriers have been identified in 5–17% of patients with FPC and BRCA1 mutations were not highly prevalent [17,18,19,20]. Overall risk for breast cancer and ovarian cancer is 55–70% and 40–45% for BRCA1 mutant carriers, respectively, and 45–70% and 15–20% for BRCA2 mutant carriers, respectively [21,22,23,24]. The relative risk for breast cancer and ovarian cancer is 5.9 (95% confidence interval (CI): 5.3–6.7) and 11.8 (95% CI: 10.0–14.0) for BRCA1 mutant carriers, respectively, and 3.3 (95% CI: 3.0–3.7) and 5.3 (95% CI: 4.4–6.3) for BRCA2 mutant carriers, respectively [25]. The lifetime risk of pancreatic cancer is about 1% for BRCA1 mutant carriers and 4.9% for BRCA2 mutant carriers [26,27]. The relative risk for pancreatic cancer in BRCA1 and BRCA2 mutant carriers is 2.3 and 3.5–10, respectively [26,28,29]. Compared to breast cancer and ovarian cancer, BRCA1/2 mutations alone do not pose a significant risk of pancreatic cancer."

**Your verdicts (pass/partial/fail):**
- direction: pass
- groundedness: pass (The full text now provides exact support for the ~4-fold and ~20-fold relative risks, as well as the ~1% and 5-10% lifetime risks)
- says_not_found (should NOT have refused): pass

---

## brca_prs_ovarian_risk_ord_001

**Query:** What does the literature report about polygenic risk score modification of ovarian cancer risk in BRCA1/BRCA2 mutation carriers?

**Gold direction:** increased risk with higher polygenic risk score  
**Gold strength:** OC risk 6% by age 80 at 10th percentile of OC-PRS vs 19% at 90th percentile, in both BRCA1 and BRCA2 carriers (15,252 BRCA1 and 8,211 BRCA2 carriers)

**System said not_found:** False
**System answer:**
> Studies show that ovarian cancer risk in BRCA1 and BRCA2 mutation carriers varies across polygenic risk score percentiles, with higher PRS associated with higher cumulative risk, and the association is quantified as per‑standard‑deviation hazard ratios (see figures and hazard‑ratio analyses) [2][4][7].

**System's cited claims, resolved to real source text:**

1. Claim: "Polygenic risk scores stratify ovarian cancer risk in BRCA1 carriers"
   Cited source (PMC8904525, body): "FigureS1: Cumulative risk of ovarian cancer risk in BRCA1 carriers by polygenic risk score percentiles. The lasso (A) and elastic net (B) penalized regression models were applied to individual level g"

2. Claim: "Polygenic risk scores stratify ovarian cancer risk in BRCA2 carriers"
   Cited source (PMC8904525, body): "Figure S2:Cumulative risk of ovarian cancer risk in BRCA2 carriers by polygenic risk score percentiles. The lasso (A) and elastic net (B) penalized regression models were applied to individual level g"

3. Claim: "Associations are quantified as per‑standard‑deviation hazard ratios with confidence intervals"
   Cited source (PMC5408990, body): "Per-standard-deviation hazard ratios and 95% confidence intervals for the associations of polygenic risk scores with breast and ovarian cancer risk in BRCA1 and BRCA2 carriers*"

**Your verdicts (pass/partial/fail):**
- direction: pass
- groundedness: partial (The cited text consists of figure captions and table titles describing the models used, but lacks the explicit data confirming the positive directional relationship between PRS and risk)
- says_not_found (should NOT have refused): pass

---

## chek2_1100delc_prognosis_disagree_001

**Query:** What does the literature report about CHEK2 c.1100delC carriers and breast cancer prognosis outcomes?

**Gold direction:** mixed  
**Gold strength:** moderate

**Gold disagreement (what the sources actually conflict about):** PMC4150261 (2014) studies survival and contralateral breast cancer in CHEK2 1100delC carriers, finding higher risks in mutation carriers. PMC12702395 (2026) explicitly states 'Against our expectations based on the results from previous studies, CHEK2 c.1100delC associated ER-positive breast cancer patients had similar recurrent disease-free survival, distant disease-free survival, breast cancer-specific survival and overall survival as compared to non-carriers', attributing the discrepancy to modern treatment regimens and HER2-targeted therapy availability since 2006.

**System said not_found:** False
**System answer:**
> The literature is conflicted: several studies and a meta‑analysis (e.g., [7]) reported that CHEK2 c.1100delC carriers have a worse breast cancer prognosis compared with non‑carriers, while a newer analysis focusing on ER‑positive disease found no worse outcome for carriers ([4]).

**System's cited claims, resolved to real source text:**

1. Claim: "Most studies showed a worse outcome for CHEK2 c.1100delC carriers"
   Cited source (PMC12702395, body): "We identified seven publications that studied one of the prognosis-related outcomes [7,[10], [11], [12], [13], [14]]. One study only describing recurrent disease-free survival was excluded [12], as this study also defined contralateral breast cancer as a recurrent disease (Supplementary Tables 7–8). Almost all studies showed a worse outcome compared to the non-carriers. Sample size of heterozygotes ranged from 34 to 963 within studies, all were tested in research setting for presence of CHEK2 c.1100delC. Most studies compared the prognosis of CHEK2 c.1100delC (also) with sporadic breast cancer patients, rather than with exclusively familial breast cancer patients. The majority of the patients were diagnosed before 2006. The majority of the studies included Dutch CHEK2 c.1100delC breast cancer patients. As a result, there is a considerable overlap of CHEK2 c.1100delC heterozygotes between studies."

2. Claim: "Recent analysis showed no worse outcome for ER‑positive CHEK2 c.1100delC breast cancer patients"
   Cited source (PMC12702395, body): "Fourth, the definitions of outcomes are not always clearly described in the previous papers, especially regarding recurrent disease occurrences. Studies in our meta-analysis describing recurrent disease did not specify whether e.g. the occurrence of a second (contralateral) breast cancer diagnosis was defined as recurrent disease [7,8,12]. Increased risks of second (contralateral) breast cancer diagnosis have been described for CHEK2 c.1100delC breast cancer patients [[2], [3], [4], [5],11], and could therefore have been a reason for the increased risk of recurrent disease reported previously. Based on current literature, second (contralateral) breast cancer is often considered as a new primary breast cancer diagnosis [26,27], rather than a recurrent disease. However, these results have influenced the medical knowledge on prognosis, and more specifically on recurrent disease, for CHEK2 c.1100delC-associated breast cancer patients. Our current analysis is the first study on recurrent diseases and distant diseases specifically in ER-positive breast cancer patients, showing no worse outcome for CHEK2 c.1100delC breast cancer patients compared to non-carriers."

3. Claim: "Published studies have pointed out a worse breast cancer prognosis for c.1100delC carriers"
   Cited source (PMC7763663, body): "Breast cancer in the carriers of pathogenic germline CHEK2 mutations has several recurrently reported clinicopathological characteristics. The most striking is the development of bilateral breast cancer, as shown in some studies (Table 1). A recent meta-analysis by Akdeniz and colleagues [181] computed the relative risk of contralateral breast cancer development as 2.68 (95% CI 1.69–3.65) for c.1100delC mutation carriers versus noncarriers (which was fully comparable with that in BRCA2 mutation carriers: RR = 2.75; 95% CI 1.77–4.29). A significantly younger cancer onset in CHEK2 mutation carriers has been reported less consistently [152,154,182]. Published studies have also pointed out a worse breast cancer prognosis for c.1100delC mutation carriers [183,184,185,186] but not for p.I157T carriers [187]. Since the first studies, CHEK2 germline mutations have frequently been associated (in 85–90% of cases) with estrogen receptor positive (ER+) breast cancer subtypes [115,126,139,183,188,189]. Consistent with that, no CHEK2 mutation carriers were observed in an analysis of 1824 triple negative breast cancer patients [190]. A large analysis conducted by the BCAC consortium estimated the cumulative risk of developing ER+ and ER− breast cancer by the age of 80 for c.1100delC mutation carriers at 20% and 3%, respectively, compared with 9% and 2%, respectively, in the general British population [155]."

**Your verdicts (pass/partial/fail):**
- direction: pass
- groundedness: pass (Claim 2 is now fully supported by the un-truncated text confirming no worse outcome for ER-positive patients)
- disagreement: pass
- says_not_found (should NOT have refused): pass

---

## chek2_c583a_g_ovarian_neg_001

**Query:** What does the literature report about CHEK2 c.583A>G and ovarian cancer risk?

**Gold:** negative case, expected_not_found = true (this variant/condition pair is deliberately absent from the corpus).

**System said not_found:** True
**System answer:**
> None of the provided excerpts mention the CHEK2 c.583A>G variant in relation to ovarian cancer risk, so the literature does not report an effect for this specific variant.

**System's cited claims:** none.

**Your verdicts (pass/partial/fail):**
- says_not_found: pass

---

## palb2_breast_risk_ord_001

**Query:** What does the literature report about PALB2 germline mutations and breast cancer risk?

**Gold direction:** increased risk  
**Gold strength:** moderate overall (OR 5.23, 95% CI 2.84-9.65), higher in women 30 or younger (OR 10.09, 95% CI 3.95-25.79)

**System said not_found:** False
**System answer:**
> The literature reports that germline PALB2 mutations raise breast cancer risk. They confer a moderate overall increase (approximately 2‑3‑fold) and a pronounced risk for women diagnosed at age 30 or younger, with estimates of about a 53% lifetime risk for carriers.

**System's cited claims, resolved to real source text:**

1. Claim: "PALB2 germline mutations confer a moderately increased risk for breast cancer"
   Cited source (PMC7384117, abstract): "This study revealed a comprehensive spectrum of PALB2 germline mutations and characteristics of PALB2‐related breast cancer in China. PALB2 germline mutations confer a moderately increased risk for breast cancer but profoundly increase breast cancer risk for those 30 years old or younger in the Chinese population."

2. Claim: "PALB2 germline mutations profoundly increase breast cancer risk for those 30 years old or younger"
   Cited source (PMC7384117, abstract): "This study revealed a comprehensive spectrum of PALB2 germline mutations and characteristics of PALB2‐related breast cancer in China. PALB2 germline mutations confer a moderately increased risk for breast cancer but profoundly increase breast cancer risk for those 30 years old or younger in the Chinese population."

3. Claim: "Monoallelic PALB2 pathogenic mutations are associated with a relative risk of about 2–3"
   Cited source (PMC5141575, body): "Monoallelic germline pathogenic mutations in PALB2, BRIP1 and ATM have been shown to be associated with an increased breast cancer relative risk of approximately 2–3.28, 29, 30, 31, 32 Biallelic pathogenic mutations in PALB2 and BRIP1 have been observed in patients with Fanconi's anaemia, resulting in their alternative names of FANCN and FANCJ, respectively.33, 34 More recently, BRIP1 pathogenic mutations have also been demonstrated in patients with ovarian cancer.35 The frequency of germline PALB2 pathogenic mutations in ovarian cancer cases does not appear increased as compared with the general population.36"

4. Claim: "Women with germline PALB2 mutations have an estimated 53% risk of breast cancer by age 80"
   Cited source (PMC8835700, body): "PALB2 is the partner and localizer of BRCA2. The PALB2 protein binds with the BRCA2 protein and stabilizes it in the nucleus. Germline mutations of PALB2 increase the risk of pancreatic cancer; although, the risk is lower than that of breast cancer. PALB2 mutations have been found in 2.1–4.9% of FPC kindreds [11,30,31]. According to a study of 524 families with germline PALB2 mutations, the risk of pancreatic cancer was estimated to be 2–3% by age 80, compared to an estimated 53% risk of breast cancer in women [32]."

**Your verdicts (pass/partial/fail):**
- direction: pass
- groundedness: partial (Claim 4 is contextually accurate, but the explicit "53%" figure is physically truncated in the provided source text)
- says_not_found (should NOT have refused): pass

---

## palb2_c1592del4_pancreatic_neg_001

**Query:** What does the literature report about PALB2 c.1592del4 and pancreatic cancer risk?

**Gold:** negative case, expected_not_found = true (this variant/condition pair is deliberately absent from the corpus).

**System said not_found:** True
**System answer:**
> None of the provided excerpts mention the specific PALB2 c.1592del4 variant in relation to pancreatic cancer risk; they only discuss PALB2 truncating variants in general.

**System's cited claims:** none.

**Your verdicts (pass/partial/fail):**
- says_not_found: pass

---

## tp53_chondrosarcoma_survival_ord_001

**Query:** What does the literature report about TP53 mutations and survival outcomes in chondrosarcoma?

**Gold direction:** worse survival (prognostic, not susceptibility)  
**Gold strength:** independent predictor in multivariable analysis, n=109 patients

**System said not_found:** True
**System answer:**
> None of the provided excerpts link TP53 mutations to survival outcomes in chondrosarcoma; they either discuss TP53 in cell lines or other tumor types without survival data.

**System's cited claims:** none.

**Your verdicts (pass/partial/fail):**
- direction: fail
- groundedness: fail
- says_not_found (should NOT have refused): fail (The system incorrectly refused a valid query with an established gold direction) 

---
